Fig. 10From: Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysisSensitive analysis evaluated heterogeneity of OS cohort, PFS cohort and related subgroups. (a) Evaluation in OS group: total, 2-yr and 3-yr. (b) Evaluation in PFS group: total, 2-yr, and 3-yr. OS, overall survival; PFS, progression-free survivalBack to article page